Conjunctivitis Treatment Market Analysis By Akron Incorporated, USV Private Limited, Bausch Health

Conjunctivitis Treatment Market By Type (Allergic Conjunctivitis, Infectious Conjunctivitis, Chemical Conjunctivitis), Therapy Type (Antibiotic Therapy and Eye Warming Therapy), Drugs (Antibiotics, Ophthalmic Steroids, Non-Steroidal Anti-Inflammatory Drugs, Antihistamines and Others),  Route of Administration (Oral and Topical),  End- users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Global Conjunctivitis Treatment Market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing population of stye population worldwide and emergence of drugs used in the treatment of risk associated with stye disease are the key factors to drive the market growth.

Download Sample Copy of Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-conjunctivitis-treatment-market

Few of the major competitors currently working in the global conjunctivitis treatment market are Nicox, Eyevance Pharmaceuticals LLC, ALLERGAN, Novartis AG, Aurobindo Pharma, Cipla Inc, Mylan .N.V, WOCKHARDT, Akron Incorporated, USV Private Limited, Bausch Health, Teva Pharmaceutical Industries Ltd, LUPIN, Dr. Reddy’s Laboratories Ltd, Mankind Pharma, Micro Labs Ltd and many others.

Market Definition:

Stye is also known as hordeolum is a ocular disease in which small lumps grows at the edge of eyelids or at the base of the eyelashes. It is caused by bacterial infections. The patients with stye may experience inflammation of eyes, swelling and tearing.

According to the article published in obson Medical Information LLC, it is estimated that total population of allergic conjunctivitis is up to 30 % of general population worldwide. Exposure to certain toxin or change in environment may increase the stye infections and prevalence of stye infections is the key factors for market growth.

Market Drivers

  • Ongoing clinical trial studies being carried out by many pharmaceuticals industries
  • Exposure to certain toxin or change in environment may increase the stye infections
  • Prevalence of indoor as well as outdoor allergens.
  • Increase in prevalence rate of stye disease worldwide

Market Restraints

  • Effective treatment is either unavailable or unaffordable.
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market.
  • Inadequate knowledge about stye disease in some developing countries

Segmentation: Global conjunctivitis Treatment Market

By Type

  • Allergic Conjunctivitis
  • Infectious Conjunctivitis
  • Chemical Conjunctivitis

By Therapy Type

  • Antibiotics Therapy
  • Eyes Warming Therapy

By Drug Class

  • Antibiotics
    • Gatifloxacin
    • Moxifloxacin
    • Tobramycin
    • Others
  • Ophthalmic Steroids
    • Dexamethasone
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • Diclofenac
  • Antihistamines
    • Lodoxamide
    • Olopatadine hydrochloride
    • Cetirizine
  • Others

By Route of administration

  • Oral
  • Topical

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • US.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market:

In December 2018, Alembic Pharmaceuticals Limited received an abbreviated New Drug application approval from the FDA for olopatadine hydrochloride, selective H1-receptor antagonist for the treatment of allergic conjunctivitis. The approval of olopatadine hydrochloride strengthens the company’s generic portfolio as well as improves the treatment paradigms for parients suffering from allergic conjunctivitis.

In June 2017, Nicox received an approval from the FDA for Zerviate (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. The approval of Zerviate marks an important commercial milestone to bring first topical ocular formulation of cetirizine, a second generation antihistamine and improve the millions of people sufferinf from conjunctivitis.

Reasons to Purchase this Report

  • Current and future global conjunctivitis treatment market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period

View Full TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-conjunctivitis-treatment-market